Journal of psychopharmacology (Oxford, England)
November 1, 2014
Eduardo Ekman Schenberg, Maria Angélica De Castro Comis, Bruno Rasmussen Chaves et al.
110 citations
Ibogaine, an alkaloid used to treat drug dependence, is illegal in some countries but unregulated in Brazil, where it is combined with psychotherapy. A retrospective analysis of 75 former alcohol, cannabis, cocaine, and crack users (72% poly-drug users) found no serious adverse reactions or fatalities. 61% of participants remained abstinent. Those treated with ibogaine once reported a median abstinence of 5.5 months; those treated multiple times, 8.4 months. Both single and multiple treatments resulted in longer abstinence than before the first session. The findings suggest that physician-supervised ibogaine with psychotherapy can facilitate prolonged abstinence without fatalities, indicating it may be a safe and effective treatment for stimulant and other non-opiate drug dependence.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
January 1, 2021
Alvaro V Jardim, Dora V Jardim, Bruno Rasmussen Chaves et al.
54 citations
In Brazil's first clinical trial of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), three patients with PTSD from sexual abuse completed treatment. The protocol involved 15 weekly therapy sessions, with three sessions including orally administered MDMA combined with psychotherapy and music, spaced about a month apart. Two months after the final MDMA session, all three patients showed clinically significant improvement, with CAPS-4 scores dropping by more than 30% from baseline. Final scores were 61, 27, and 8, down from 90, 78, and 72. No serious adverse events occurred; common side effects were somatic pains and anguish. Secondary outcomes also improved. MDMA-assisted psychotherapy could become a viable PTSD treatment in Brazil.
Research Square
September 8, 2022
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al.
A bibliometric analysis of publications on ibogaine for treating substance-related disorders from 1991 to 2020 found that research output grew steadily, with an increase of 5.1 publications per year between 1991 and 2000. The subsequent two decades showed continued but fluctuating publication volumes, with the United States being the most prominent contributor. The analysis suggests that despite variations over time, research on ibogaine persists and points toward future directions for public health interventions.